Aaron Boster

And what's exciting is that it was a very successful result.

Compared to placebo, the patients on the BTK inhibitor slowed progression by 29%, which is a really big deal.

This medication has been fast-tracked at the American FDA, and we believe that probably come September timeframe, we may have the first FDA-approved therapy for non-relapsing secondary progressive MS.

What's even more exciting is that the same molecule, the telobrutinib molecule, is being studied in primary progressive MS in a clinical trial called the Perseus trial.

Now, we should be getting a readout for Perseus sometime later this year, and our fingers are crossed.

I'll cross my fingers for you.

How crestfallen are you?

My honest answer is I don't think that we're going to see a cure in my lifetime.

Yeah.

And I'm not saying that to be a Debbie Downer.

The reason I say that is our understanding of the immune system remains fledgling.

We, for example, are just now starting to be able to impact the innate immune response, which is bigger than the adaptive immune response.

So most of our drugs that we've developed affect B and T cells.

There's another part of our immune system, which is way bigger than that.

And we're just now studying drugs that can get at it.

I think given our meager understanding of the immune system, which is really one of the last frontiers, I think it's unrealistic that we're going to cure MS in the near term.

Now, I want to be really clear that in medicine, we cure nearly nothing.

So we don't cure high blood pressure.

We treat high blood pressure.

So I have high cholesterol.